Finasteride Tablet, Film Coated
Product Images NDC 71335-1898

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 71335-1898). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Finasteride Figure 1 (Finasteride Fig.1)

A line graph showing mean change from baseline over 4 years comparing Finasteride and placebo. The y-axis measures mean change from baseline ± 1 SE, spanning 0 to -6, and the x-axis shows time points from baseline through year 4. Data points indicate a greater mean change reduction for Finasteride than placebo throughout the period. Sample sizes for each group at each time point are noted below the x-axis.*

FDA Label Image

Finasteride-fig.2 (Finasteride Fig.2)

A line graph comparing the percent of patients over 48 months in two groups: Finasteride and Placebo. The y-axis represents the percent of patients up to 15%, and the x-axis shows observation time in months from 0 to 48. The Finasteride group has a lower cumulative percentage compared to the Placebo group. Below the graph are tables listing cumulative event numbers and patients at risk per year for both groups.*

FDA Label Image

Finasteride Figure 2 (Finasteride Fig.3)

A line graph showing mean percent change from baseline over four years for Finasteride 5 mg and placebo groups. The vertical axis represents mean percent change with error bars (±1 SE), and the horizontal axis indicates time points from baseline to year 4. Finasteride data points decrease below baseline, while placebo data points increase above baseline over time. Sample sizes are listed below each time point for both groups.*

FDA Label Image

Finasteride Figure 4 (Finasteride Fig.4)

A line graph showing percentage of events over time by treatment group. The x-axis represents years from randomization (0 to 5.5 years), and the y-axis shows percent with event (0 to 25%). Four lines are plotted: Placebo, Finasteride, Doxazosin, and Combination. Placebo group shows the highest event rate over time, followed by Finasteride and Doxazosin, with the Combination group having the lowest event percentage.*

FDA Label Image

Structutre (Finasteride Structure)

Chemical structure diagram of the active ingredient Finasteride used in the medication Finasteride 5 mg film-coated tablets by Bryant Ranch Prepack.*

FDA Label Image

Fig 3finasteride

A line graph showing cumulative percentages of patients over 48 months comparing Finasteride and placebo groups. The y-axis represents the percent of patients (0% to 15%), and the x-axis shows observation time in months (0 to 48). Two lines are plotted: a solid line for Finasteride and a dotted line for placebo. Below the graph, a table displays the number of cumulative events and patients at risk at specified intervals for both groups.*

FDA Label Image

Label (Lbl713351898)

Finasteride 5 mg film-coated oral tablet label packed by Bryant Ranch Prepack, Burbank CA. The label compares the product to Proscar 5 mg tablet by Alkem Laboratories Limited. It shows storage instructions at 20°-25°C (68°-77°F) and includes lot number 1523487, a bar code, and NDC 7133518981. The package count is 100 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.